Synaptixbio Ltd

DataGardener
live
Micro

Synaptixbio Ltd

13318389Private Limited With Share Capital

9400 Garsington Road, Oxford Business Park, Oxford, OX42HN
Incorporated

07/04/2021

Company Age

5 years

Directors

5

Employees

3

SIC Code

72110

Risk

low risk

Company Overview

Registration, classification & business activity

Synaptixbio Ltd (13318389) is a private limited with share capital incorporated on 07/04/2021 (5 years old) and registered in oxford, OX42HN. The company operates under SIC code 72110 - research and experimental development on biotechnology.

Overviewsynaptixbio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases. synaptixbio’s mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or muta...

Private Limited With Share Capital
SIC: 72110
Micro
Incorporated 07/04/2021
OX42HN
3 employees

Financial Overview

Total Assets

£3.78M

Liabilities

£217.8K

Net Assets

£3.56M

Cash

£2.33M

Key Metrics

3

Employees

5

Directors

18

Shareholders

Board of Directors

4

Filed Documents

34
Confirmation Statement With No Updates
Category:Confirmation Statement
Date:24-04-2026
Change Person Director Company With Change Date
Category:Officers
Date:24-04-2026
Accounts With Accounts Type Total Exemption Full
Category:Accounts
Date:20-06-2025
Confirmation Statement With Updates
Category:Confirmation Statement
Date:28-04-2025
Capital Allotment Shares
Category:Capital
Date:24-07-2024
Capital Allotment Shares
Category:Capital
Date:08-07-2024
Accounts With Accounts Type Total Exemption Full
Category:Accounts
Date:28-06-2024
Capital Allotment Shares
Category:Capital
Date:18-04-2024
Confirmation Statement With Updates
Category:Confirmation Statement
Date:08-04-2024
Capital Allotment Shares
Category:Capital
Date:02-02-2024
Accounts With Accounts Type Total Exemption Full
Category:Accounts
Date:04-09-2023
Resolution
Category:Resolution
Date:10-08-2023
Memorandum Articles
Category:Incorporation
Date:10-08-2023
Notification Of A Person With Significant Control Statement
Category:Persons With Significant Control
Date:04-05-2023
Cessation Of A Person With Significant Control
Category:Persons With Significant Control
Date:04-05-2023
Capital Allotment Shares
Category:Capital
Date:03-05-2023
Confirmation Statement With Updates
Category:Confirmation Statement
Date:12-04-2023
Capital Allotment Shares
Category:Capital
Date:23-02-2023
Capital Alter Shares Subdivision
Category:Capital
Date:04-01-2023
Capital Allotment Shares
Category:Capital
Date:21-12-2022
Accounts With Accounts Type Total Exemption Full
Category:Accounts
Date:06-12-2022
Change Account Reference Date Company Current Shortened
Category:Accounts
Date:21-10-2022
Resolution
Category:Resolution
Date:05-10-2022
Memorandum Articles
Category:Incorporation
Date:05-10-2022
Confirmation Statement With Updates
Category:Confirmation Statement
Date:10-05-2022
Capital Allotment Shares
Category:Capital
Date:05-05-2022
Notification Of A Person With Significant Control
Category:Persons With Significant Control
Date:28-04-2021
Withdrawal Of A Person With Significant Control Statement
Category:Persons With Significant Control
Date:27-04-2021
Notification Of A Person With Significant Control Statement
Category:Persons With Significant Control
Date:26-04-2021
Capital Allotment Shares
Category:Capital
Date:23-04-2021
Cessation Of A Person With Significant Control
Category:Persons With Significant Control
Date:22-04-2021
Capital Allotment Shares
Category:Capital
Date:22-04-2021
Change Person Director Company With Change Date
Category:Officers
Date:12-04-2021
Incorporation Company
Category:Incorporation
Date:07-04-2021

Innovate Grants

2

This company received a grant of £498602.0 for The Treatment Of Rare Paediatric Tubb4A-Related Leukodystrophiescs For The Treatment Of Rare Paediatric Tubb4A-Related Leukodystrophies. The project started on 01/11/2023 and ended on 31/10/2025.

This company received a grant of £1999008.0 for The Treatment Of A Rare Paediatric Tubb4A-Related Leukodystrophy - A First-In-Human Clinical Triale Paediatric Tubb4A-Related Leukodystrophy - A First-In-Human Clinical Trial. The project started on 01/07/2024 and ended on 30/06/2027.

Risk Assessment

low risk

International Score

Future Factor

excellent

Performance Rating

Accounts

Typetotal exemption full
Due Date30/09/2026
Filing Date20/06/2025
Latest Accounts31/12/2024

Trading Addresses

9400 Garsington Road, Oxford Business Park, Oxford, Ox4 2Hn, OX42HNRegistered

Contact

synaptixbio.com
9400 Garsington Road, Oxford Business Park, Oxford, OX42HN